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Learning Objectives 
 Summarize the current trends in genetic/genomic testing 
 Discuss how genetic testing is regulated and reimbursed in 
the United States 
 Explain how genetic tests are assessed in terms of the 
evidence, including challenges and pitfalls 
 Understand implications for population health 
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 Nonprofit health services research organization 
 47 years of laboratory-based medical device evaluations 
 25 years conducting Health Technology 
assessment/forecasting/comparative-effectiveness research 
 Worldwide clients number in the thousands 
■ Hospitals and health systems 
■ Private third-party payers 
■ Government agencies (state and federal) 
 For Agency for Healthcare Research and Quality (AHRQ) 
■ ECRI Institute Evidence-based Practice Center since 1997 
■ National Guideline Clearinghouse; National Quality Measures 
Clearinghouse 
■ Healthcare Horizon Scanning System (2010 – 2015) 





About ECRI Institute 
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Integrity 
 Neither ECRI nor any of its staff has a financial interest in 
the sale of any medical technology. ECRI and its staff are 
not permitted to accept royalties, gifts, finder’s fees, 
grants, or commissions from the medical device or 
pharmaceutical industries and are not permitted to own 
stock in or undertake consulting work for such industries. 
 Adhering to our conflict-of-interest rules—but also 
interacting with manufacturers and labs—are part of our 
culture 
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 Secretary's Advisory Committee on Genetics, Health, and 
Society (SACGHS): very broad definition (2008) 
 A genetic or genomic test involves an analysis of human 
chromosomes, DNA, RNA, genes and/or gene products (eg, 
enzymes and other types of proteins) which is 
predominantly used to detect heritable or somatic 
mutations, genotypes or phenotypes related to disease and 
health. 
■ Genetic test: analyzes single gene to a few genes 
■ Genomic test: analyzes entire, or large portion, of the genome 
 Will focus today on tests that detect mutations in tumors:  
cancer genomic tests 
 
Genetic/Genomic Test Definition 
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Current Trends in Genetic/Genomic 
Testing 
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Whole genome/exome sequencing 
becomes increasingly available 
■ Cheaper 
■ Quicker 
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Personalized Medicine 
 Customizing treatment for individual patients 
■ Not a new concept 
 Its effectiveness and safety depend on how well clinicians 
understand each person's unique characteristics 
 The area has been rapidly evolving during the past several 
decades  
■ Mainly due to the advance in genetic science and 
technologies 
■ Genetic testing can provide crucial information to accurately 
predict risk of developing disease, disease progression and 
response to treatment 
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Example:  Personalized Medicine Approach 
to Treating Non Small Cell Lung Cancer 
(NSCLC)  
 The most common type of lung cancer 
 Mutations in the EGFR gene are present in about 10 
percent of NSCLC tumors 
 The therascreen EGFR RGQ PCR Kit was approved by FDA 
as a companion diagnostic test 
 EGFR mutation testing has been used routinely to select 
candidates for erlotinib or gefitinib 
 Multigene panels can also include EGFR 
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Genetic Tests Present Huge Challenges 
 ~$20 billion spent on genetic testing in 2015 
 Increasing complexity of multigene test 
panels and underlying platforms 
 Limited evidence  
 Aggressive direct-to-consumer and provider 
marketing 
 Concerns about 
ordering/interpretation/patient counseling 
 Intensive time/resources needed to get 







Source:  GeneTests.org 
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Many tests; different purposes   
 ECRIgene classifies tests into 8 
categories: 
 Carrier screening   
 Diagnostic  
 Monitoring (evaluates disease state 
periodically) 
 Pharmacogenetic/pharmacogenomic  
 Preimplantation screening  
 Prenatal screening  
 Prognostic  
 Risk assessment or general screening  
Modified from list at NIH Genetics Home Reference 
(https://ghr.nlm.nih.gov/primer/testing/uses) 
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Managing Genetic Testing Manages Costs  
10 
©2017 ECRI  INSTITUTE  
Regulation and Reimbursement 
 Vast majority of tests Are Laboratory-Developed Tests 
(LDTs)  
 Fewer than 100 tests have gone through the FDA 
regulatory pathway 
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Government Certification 
 Federal   
►Clinical Laboratory Amendments Act of 1988 (CLIA) 
established quality standards for lab testing (administered by 
CMS) 
►Under CLIA, CMS accredits labs  that produce Laboratory–
Developed Tests (LDTs) 
►LDTs are performed only in the lab that developed the test  
►Does not look at evidence for clinical validity of a specific test 
 State 
►7 states also have certification programs: CA,FL, MA, MD, NY, 
PA, RI 
►NY has the most rigorous 
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FDA Regulatory Pathway 
 FDA-cleared or approved test kits or systems (in vitro 
diagnostic tests = medical devices) 
►Historically, not actively regulated by FDA 
►Bar is higher for FDA-cleared tests than for LDTs 
►Can be licensed and performed in multiple labs 
 FDA may increase oversight of LDTs: high-risk tests first 
►Risk stratification still being determined 
►Labs will have to get IDEs to start collecting clinical validity 
data, and then go through the PMA process 
►FDA  already cracking down on labs marketing tests direct-to-
consumer (23andMe, Pathway Genomics, DNA4Life etc) 
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 Regulated as in vitro molecular diagnostic test kit 
 Companion diagnostic: provides information that is 
essential for the safe and effective use of a corresponding 
drug or biological product 
 Linked to a specific drug within its approved label 
 Complementary diagnostic: diagnostics that are not 
required but provide significant information about use of a 
drug  
 Complementary diagnostics associated more usually with a 
class of drugs, not confined to specific uses by FDA labeling 
 
FDA Cleared Genetic Tests 
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Companion Diagnostic Devices 
 More than two dozen companion diagnostic devices have 
been approved or cleared by FDA; mostly, for cancer drugs 
■ Herceptin (trastuzumab), Iressa (Gefitinib), Tarceva 
(Erlotinib), Mekinist (tramatenib); Tafinlar (dabrafenib), 
Erbitux (cetuximab); Vectibix (panitumumab), etc. 
 Include molecular tests, cytogenetic tests, and 
immunohistochemical tests 
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The Public Health Evidence for FDA Oversight of 
Laboratory Developed Tests: 20 Case Studies  
"... most laboratories that offer LDTs follow only the regulatory 
requirements of CLIA, which are intended to regulate the operations of 
laboratories, but are not specifically intended to regulate in vitro 
diagnostic devices."  
"Despite the contention from some that ‘CLIA is enough,’ all of the tests 
described as problematic in this report were offered from laboratories 
following the minimum requirements of CLIA." 
► High false positive and/or false negative results 
► Inflated claims of test accuracy by manufacturers 
► Lack of validation data on test 
► No clear evidence for association between test biomarker and 
disease, risk for disease, or disease prognosis (weak clinical validity) 
Office of Public Health Strategy and Analysis  
Office of the Commissioner Food and Drug Administration  
November 16, 2015  15 
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Potential for Harm 
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What ECRI Hears 
► Payers   
► “We don’t know what we are paying for.”  
► “We don’t know whether any evidence underpins this test.” 
► “Do we really need to pay for every gene in this panel?” 
► Providers   
► “Our docs are ordering tests without understanding if it’s the right test or if 
the results will be actionable.”  
► “We don’t know what the evidence is on this test.”  
► “We don’t really understand the results.” 
► “We’re under pressure. Payers are giving this a lot more scrutiny.” 
► “This test gave me no valuable information to help my patient and 
insurance refused to pay for it.” 
► Labs/manufacturers  
► “What is ECRI telling payers and providers about our test.” 
► “We need to understand how ECRI is identifying and evaluating evidence.” 
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Challenges for Payers 
 Making evidence-based coverage decisions - Lack of evidence 
showing clinical utility creates a major bottleneck for insurance 
reimbursement 
 Sources for informing coverage decisions - but each has significant 
limitations and are only available for some genetic tests  
 Professional guidelines - weigh heavily but are also limited in 
number 
 FDA oversight  - clearance is historically used as a starting point for 
test coverage, but most genetic tests are created and validated as 
laboratory-developed tests, which do not generally fall under FDA 
oversight 
 Guidance on coverage decisions - other payers may be influential, 
particularly Medicare, but their decisions may not translate well to 
genetic tests for those under the age of 65 
18 
©2017 ECRI  INSTITUTE  
Assessing the Evidence, Including 
Challenges and Pitfalls 
  
©2017 ECRI  INSTITUTE  
Assessing the Evidence Underlying 
Genetic Tests 
 Analytic Validity (AV) - how accurately test detects whether a specific 
genetic variant is present or absent 
■ Often a “black box”; we typically don’t know the quality and consistency 
of laboratory assays over time 
 Clinical Validity (CV) - how accurately the genetic information analyzed 
predicts the response to drug treatment 
 Clinical Utility (CU) – degree to which test can improve patient 
outcomes  
■ Can the test provide information about treatment or management that 
is helpful to consumers or patients?   
 Poor analytic validity will typically compromise clinical validity and 
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We seek a “Chain of Evidence” leading 
from Analytic Validity to Clinical Utility 
 Analytic validity  Clinical validity  Clinical Utility 
■ Does the test detect the genetic variant 
accurately/reliably? 
■ Does the test detect the disease/disorder accurately? 
■ Does the test affect treatment decisions? 
■ Does the treatment lead to improved health outcomes? 
■ Are there any harms associated with the testing?  
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What are the Challenges in Assessing 
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Challenges in Assessing Analytic Validity 
(AV) 
 Lack of transparency about the tests’ technical detail 
 Lack of published data 
 Data may be about a previous version of the test 
■ Does the evidence apply to the current version? 
 Lack of assessment tools for rating the quality of analytic validity 
studies. Large diversity of studies.  
 Analytic validity may vary across labs and over time 
■ Changes in type/quality of reagents 
■ Personnel changes in laboratories (rate of turnover in staff) 
■ Standardization/certification procedures 
■ Therefore, AV is often a “black box”: we can only assess whether 
output is consistent, knowledge of inner workings is not available 
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Assessing Clinical Validity (CV) 
 Ideally need diagnostic accuracy studies: compare genetic 
test performance to GS test 
 Diagnostic performance measures 
■ Sensitivity 
■ Specificity 
 Clinical performance measures 
■ Negative/Positive predictive values 
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Questions/Challenges in Assessing 
Clinical Validity 
 Is study size sufficient? 
 Is the study population correctly matched to the test’s 
intended purpose?  (Is spectrum bias minimized?) 
 Is there a substantial discrepancy between diagnostic 
performance metrics and predictive values?  If so, will 
prevalence vary across different environments where test is 
employed?  
 False negative/false positive rates.  What is the clinical fate 
of these patients without use of the test?  
 Manufacturers (mfrs) are not always clear about intended 
purpose of the test and/or the targeted patient population.  
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Evidence for Clinical utility (CU) 
 Clinical utility (the test’s impact on health outcomes) is 
usually of ultimate interest in assessing GT technologies 
 Ideal evidence is often a randomized controlled trial (RCT) 
comparing treatment with use of the GT to usual care (no 
GT) 





+ Usual Care Outcomes 
Usual Care Outcomes 
Compare 
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Challenges in  Assessing Evidence for 
Clinical Utility (CU) 
 Practical reasons for lack of direct evidence 
■ Time, resources (many small companies with LKDTs have 
limited finances for conducting large, complex trials) 
■ Difficulty in patient recruitment 
■ Long follow-up may be required while there are constant 
changes and evolution in technologies 
■ Sometimes CU follows logically from test validation and 
position in clinical pathway; additional  evidence is not 
sought by mfrs 
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Direct evidence for clinical utility is rarely 
available 
 Clinical utility (the test’s impact on health outcomes) is usually 
the ultimate interest of health technology assessment  
 Ideal type of evidence: studies that compare use versus no 
use of the test, reporting on patient-oriented health outcomes 
with sufficient follow-up 
 Practical reasons for lack of direct evidence 
■ Difficulty in patient recruitment, constant changes in technologies, 
long follow-up required 
 Some important outcomes relevant to predictive genetic tests 
are rarely studied 
■ Psychological distress 
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Case Example: FoundationOne (Foundation 
Medicine, Inc.) Comprehensive Genomic Profiling 
Test for Guiding Targeted Therapy for Cancer  
 FoundationOne 
■ A genomic profiling test intended to help physicians make 
treatment decisions for patients with all types of solid tumor 
cancers  
■ Uses next-generation sequencing  
 simultaneously examines the entire coding regions of 315 genes 
 select introns from 28 additional genes  
■ Intended purpose: To identify molecular growth drivers of 
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Is each included marker a good 
indicator for drug response? 
 Markers were selected based on literature, according 
to Foundation Medicine 
■ About 80 FoundationOne-relevant studies are provided on the 
company’s website 
 Some markers are considered well-established for 
guiding treatment decisions for certain cancers 
■ e.g., EGFR mutations and ALK fusions for lung cancer 
(adenocarcinoma), ERBB2 for breast cancer, KRAS mutations 
for colorectal cancer 
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The Main Challenge 
 The test includes a very large number of genetic biomarkers 
 Targeted to all solid tumor cancers 
 Clinical validity will not be available for all cancer types 
 Does FoundationOne affect patient outcomes (e.g., overall 
or progression-free survival)? 
  
 ECRI Evidence Report: 
 “This Product Brief is not intended to separately evaluate the clinical 
significance of each of the genes/introns included in FoundationOne for 
guiding cancer treatment. This Product Brief focuses primarily on 
evaluating the FoundationOne test’s impact as a multigene panel on 
patient-oriented health outcomes. “ 
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Does FoundationOne affect treatment 
decisions? 
 Yes, for some markers/cancer types (approx. 20%) 
■ Based on a small number of case series and single case 
reports  
 But evidence is not available for all markers/cancer 
types 
 It is questionable whether other markers included in 
the test carry the same clinical significance 
31 
©2017 ECRI  INSTITUTE  
Do treatment decisions based on 
FoundationOne results affect patient 
outcomes? 
 FoundationOne is intended to identify actionable 
genomic alterations 
■ Actionable genomic alterations — there is available an FDA-
approved drug for the cancer or a registered clinical trial on 
a drug for the cancer  
■ Most of the actionable genomic alterations are for guiding 
off-label use of targeted therapies, which may not 
necessarily improve health outcomes 
 Limited reimbursement: of ECRI’s sampling of 9 
representative payers with policies on genomic 
profiling, 2 cover with conditions, 7 consider such 
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 Simplify the Wild, Wild West of genetic testing 
 Ample and good quality published evidence 
■ Analytic Validity (test accuracy) 
■ Clinical Validity (diagnostic accuracy)  
■ Clinical Utility (impact on patient management and  health 
outcomes) 
 Ensuring appropriate access / reducing inappropriate 
utilization 
 Efficient and evidence-based policy development/updating 




What Evidence Do You Want? 
“We don’t know whether any evidence underpins this test.” CMO at ECRI 
Genetic Test Roundtable  
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 Unpublished data presented only as conference 
abstracts or posters 
 Data summaries or unsubstantiated claims from 
lab and manufacturer websites with no 
independent validation of information 
 Markov models and cost-effectiveness analyses 
based on hypothetical assumptions and inputs 
What “Evidence” Don’t You Want? 
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Impact of Genetic Testing on Population 
Health 
 Many examples where precision medicine has caused a 
paradigm shift in treatment  and achieved superior health 
outcomes 
 Challenges in developing a comprehensive genetic/genomic 
testing approach for population-based care 
 Comparatively few biomarkers where a specific mutation is 
linked to risk for developing disease, or indicative of 
response to a targeted therapy 
 Gaps in evidence exist: underlying science and data analytics 






©2017 ECRI  INSTITUTE  
Questions? 
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